Welcome to the Instem Investor Centre
Instem (AIM:INS.L) is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.
Instem’s Early Development Applications (EDA’s) are used in evaluation studies to:
- collect, analyse and report complex scientific data;
- comply with regulatory reporting requirements;
- improve quality, consistency and efficiency of information reporting; and
- reduce the time of critical path R&D activities.
Instem’s solutions are supplied to an international blue chip customer base including AstraZeneca, GlaxoSmithKline and Charles River Laboratories.
We have established a profitable, cash-generative leading business in the niche market of early drug safety assessment. With fiscal and regulatory pressures driving the need for our solutions, we believe we now have a strong platform from which to achieve accelerated growth through the entry into complementary markets and geographies. Since our Admission to AIM in October 2010 we have made progress with both our organic and acquisitive growth strategies, acquiring BioWisdom in March 2011. We look forward to the future with confidence and will build on the successful execution of our strategy so far by continuing to drive growth through both internal investment and complementary acquisitions.